Mass Spectrometers of Biopharma — improved methodologies for qualified, quantitative and structural separation of drugs. (Q84230): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item) |
(Changed an Item) |
||
| Property / beneficiary | |||
| Property / beneficiary: Institute of Biochemistry and Biophysics of Polish Academy of Sciences / rank | |||
Normal rank | |||
Revision as of 18:56, 9 June 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Mass Spectrometers of Biopharma — improved methodologies for qualified, quantitative and structural separation of drugs. |
Project in Poland financed by DG Regio |
Statements
3,499,706.0 zloty
0 references
3,499,706.0 zloty
0 references
100.0 percent
0 references
1 November 2017
0 references
31 October 2020
0 references
INSTYTUT BIOCHEMII I BIOFIZYKI POLSKIEJ AKADEMII NAUK
0 references
Mass Spectrometry (MS) expands into almost every area that requires qualitative and quantitative analysis of small molecules, including clinical applications. Its advantages include unsurpassed specificity, sensitivity better than most other analytical techniques, and ability to multiplex the analysis of many compounds in one analytical run. Since 2001 MS Lab IBB serves as a core MS laboratory for the community of biomedical sciences, implementing a variety of proteomic/metabolomic analyses for research groups from >70 institutions worldwide, both from academia and biopharma industry. It also provides immunosuppressive drug monitoring service for Polish transplant patients. We collaborate with numerous research groups from Poland and abroad, work out new data analysis tools and train students. Present project aims at improvements in analytical capabilities of the Lab and implementation of new procedures that will increase the scope of Lab activities or increase the results quality. (Polish)
0 references
Mass Spectrometers (MS) account into albridge every area sensitive analysis of small molecules, including clinical applications.Its aims are complex the analysis of many other factors in this analysis.Since 2001 MS Lab IBBs as a core MS laboratory for the community of biomecial analyses for research groups from > 70 institutions worldwide, boh from academic and Biopharma industriy.It include immunides immunosuppresisve drug monitoring service for Polish Transplant patients.Collaborative with numbers from Poland and abad, work out new date analysis tools and train students.Presentation of the scope of the Lab activities or implementation of new procedures that will increase the scope of the benefit quality. (English)
0 references
Identifiers
POIR.04.04.00-00-2CC8/16
0 references